Discussion about this post

User's avatar
Neural Foundry's avatar

That NBER paper on trial representativness is a perfect example of selection bias in action. I've seen similar issus in other fields where the sample population doesn't match the real-world target. The 15% difference in predicted SAE rates between trial enrollees and the actual target population is massive when scaled across millions of patietns.

Craig in Maine's avatar

I’m being treated for Stage IV lung cancer by one of the newer immunotherapy treatments. I presume the voluminous lists of possible side effects that accompany advertising for the drug are compiled from reports gathered during clinical trials. People who have cancer, especially those in advanced stages, have symptoms…regardless of whether they are being treated with useful drugs or placebos. It seems to me that the decision to include or exclude a given patient in the clinical trial has a very substantial effect on the overall results of the trial. I’ve often wondered how they determine if a symptom was caused by progression of the underlying disease or by the treatment.

Interesting stuff today. Do you think the tide is beginning to turn with respect to expectations for America’s universities? I fear it is wishful thinking.

8 more comments...

No posts

Ready for more?